Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma

⋮

← $

X Mark channel Not-Safe-For-Work? cancel confirm NSFW Votes: (0 votes)

X Are you the publisher? Claim or contact us about this channel.

X 0

X Search

Sharing:

Title:

URL:

Copy Share URL